Skip to main content
HCPCS J1554 · Level II · Part B drug

J1554: immune globulin (Asceniv), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J1554

Billing unit
500 MG
Inj. asceniv
ASP payment limit
$508.454
October 2026; -0.1% vs July 2026
Practitioner MUE
240
MAI 3
OPPS status
SI K
APC 9392
NCCI exposure
no PTP pairs
Coverage articles
6
27 states

TL;DR

HCPCS J1554 is the Level II code for Injection, immune globulin (asceniv), 500 mg, billed per 500 MG. The Medicare Part B ASP payment limit for October 2026 is $508.454 per billing unit, down 0.1% from July 2026. The practitioner MUE allows up to 240 units per date of service (MAI 3), so a full 240-unit day is $122,028.96 at the current limit. Under OPPS it carries status indicator K in APC 9392. J1554 is billed in units of 500 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names immune globulin: J1552 (Alyglo from GC Biopharma USA, Inc); J1556 (Bivigam); J1557 (Gammaplex from Bio Products Laboratory; intravenous route; non-lyophilized); J1561 (Gamunex-C/Gammaked; non-lyophilized); J1566 (Gammagard S/D from Takeda Pharmaceuticals America, Inc.; intravenous route; lyophilized, powder); J1568 (Octagam; intravenous route; non-lyophilized). The ASP crosswalk maps 1 NDC to it, sold as Asceniv by ADMA Biologics, Inc. 6 Medicare coverage articles list the code across 24 states plus DC and 2 territories, including A56718.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J1554 at $508.454 per 500 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $509.139 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J1554
QuarterPayment limitPerCoinsurance
October 2026$508.454500 MG20%
July 2026$509.139500 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J1554. Report the NDC in the claim's drug segment and bill the number of J1554 units that equals the quantity administered divided by 500 MG; the last column gives units per full package.

NDCs that crosswalk to J1554
NDCDrug nameLabelerPackage sizeBilling units / package
69800-0250-01AscenivADMA Biologics, Inc50 × 110

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J1554. For practitioners the limit is 240 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J1554 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services2403 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital2403 Date of Service Edit: ClinicalPrescribing Information
DME supplier2403 Date of Service Edit: ClinicalPrescribing Information

MUE for J1554 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J1554 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J1554 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J1554 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

6 current Medicare Administrative Contractor articles list J1554 in their HCPCS tables, covering 27 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J1554
ArticleTitleContractor(s)StatesRelated LCD
A56718Billing and Coding: Intravenous Immunoglobulin (IVIG)Palmetto GBANC SC VA WVL34580
A56786Billing and Coding: Immune GlobulinNovitas Solutions, Inc.DC DE MD NJ PAL35093
A57187Billing and Coding: Immune Globulin Intravenous (IVIg)Noridian Healthcare Solutions, LLCAZ MT ND SD UT WYL34314
A57554Billing and Coding: Immune GlobulinsWisconsin Physicians Service Insurance CorporationIA KS MO NEL34771
A57778Billing and Coding: Immune GlobulinFirst Coast Service Options, Inc.FL PR VIL34007
A59105Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG)Wellpoint FederalCT IL MN NY WIL39314

Diagnoses Medicare contractors cover for J1554

6 billing and coding articles attach a covered diagnosis list to J1554: 448 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J1554
ICD-10-CMDescription (FY2027)Articles covering
C90.00Multiple myeloma not having achieved remission6 of 6
C90.02Multiple myeloma in relapse6 of 6
C91.10Chronic lymphocytic leukemia of B-cell type not having achieved remission6 of 6
C91.12Chronic lymphocytic leukemia of B-cell type in relapse6 of 6
D59.0Drug-induced autoimmune hemolytic anemia6 of 6
D59.11Warm autoimmune hemolytic anemia6 of 6
D59.12Cold autoimmune hemolytic anemia6 of 6
D59.13Mixed type autoimmune hemolytic anemia6 of 6
D69.3Immune thrombocytopenic purpura6 of 6
D80.0Hereditary hypogammaglobulinemia6 of 6
D80.1Nonfamilial hypogammaglobulinemia6 of 6
D80.2Selective deficiency of immunoglobulin A [IgA]6 of 6
D80.3Selective deficiency of immunoglobulin G [IgG] subclasses6 of 6
D80.4Selective deficiency of immunoglobulin M [IgM]6 of 6
D80.5Immunodeficiency with increased immunoglobulin M [IgM]6 of 6
433 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J1554 are counted here: a group whose instructions name J1554, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J1554, by article
ArticleContractorGroups that applyCovered codes for J1554Full list
A56718Palmetto GBAone list for every code in the article212On LCD L34580
A56786Novitas Solutions, Inc.group 1 applies to J1554108On LCD L35093
A57187Noridian Healthcare Solutions, LLCone list for every code in the article103On LCD L34314
A57554Wisconsin Physicians Service Insurance Corporationgroup 13 applies to J1554183On LCD L34771
A57778First Coast Service Options, Inc.group 1 applies to J1554108On LCD L34007
A59105Wellpoint Federalone list for every code in the article307On LCD L39314

Local coverage policies that list J1554

7 active Local Coverage Determinations list J1554 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J1554 carries status indicator K and is assigned to APC 9392, with a published national unadjusted payment of $508.454. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J1554 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $508.45 per 500 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J1554 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J1554

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J1554

What does HCPCS code J1554 describe?

J1554 is defined by CMS as "Injection, immune globulin (asceniv), 500 mg". Each billing unit represents 500 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J1554 a CPT code?

No. J1554 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as immune globulin (Asceniv); CPT codes are five-character codes maintained by the AMA. On a Part B claim J1554 reports the drug itself in 500 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J1554 in October 2026?

The ASP-based payment limit is $508.454 per 500 MG, with 20% beneficiary coinsurance. The July 2026 limit was $509.139. Commercial payers use their own fee schedules.

How many units of J1554 can be billed per day?

The practitioner Medically Unlikely Edit is 240 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J1554?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Asceniv (ADMA Biologics, Inc). For example NDC 69800-0250-01 (package size 50) equals 10 billing units of J1554.

Does J1554 have NCCI bundling edits?

No active practitioner PTP pairs list J1554 as a column-1 or column-2 code in the v323r0 release.

J1554 vs J1552: what is the difference?

Both are HCPCS Level II codes whose descriptor names immune globulin. What sets J1552 apart: Alyglo from GC Biopharma USA, Inc. J1554 is billed per 500 mg, limit $508.454, MUE 240; J1552 is billed per 500 mg, limit $120.04, MUE 1200. Report the code whose descriptor matches the product and setting in the record.

J1554 vs J1556: what is the difference?

Both are HCPCS Level II codes whose descriptor names immune globulin. What sets J1556 apart: Bivigam. J1554 is billed per 500 mg, limit $508.454, MUE 240; J1556 is billed per 500 mg, limit $80.791, MUE 240. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J1554?

6 current Billing and Coding Articles in the Medicare Coverage Database list J1554, covering 24 states plus DC and 2 territories: A56718 (Billing and Coding: Intravenous Immunoglobulin (IVIG)); A56786 (Billing and Coding: Immune Globulin); A57187 (Billing and Coding: Immune Globulin Intravenous (IVIg)).

What diagnosis codes support J1554?

6 Medicare billing and coding articles list 448 covered ICD-10-CM codes for J1554 between them, for example C90.00 (Multiple myeloma not having achieved remission); C90.02 (Multiple myeloma in relapse); C91.10 (Chronic lymphocytic leukemia of B-cell type not having achieved remission); C91.12 (Chronic lymphocytic leukemia of B-cell type in relapse); D59.0 (Drug-induced autoimmune hemolytic anemia). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

CMS guidance

The Medicare Learning Network publication that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.